An interventional study of Oleanolic acid-enriched olive oil and Pomace olive oil in Alzheimer s Disease and Prodromal Alzheimer's Disease, sponsored by Spanish National Research Council. Not yet recruiting at 1 site in Spain. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Spanish National Research Council · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 162nd largest by planned enrollment of the 240 interventional ones that give a count, is the only one that started in 2027, is one of 66 with no phase, reaches primary completion later than 59 of the 79 other live ones, and was the 278th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Spanish National Research Council is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Spanish National Research Council has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease begins many years before memory problems become obvious. People in the early ("prodromal") stage have memory complaints but are still independent in daily life. At present there is no treatment that prevents this stage from progressing to dementia.
Olive oil contains two natural compounds, oleanolic acid and erythrodiol. Earlier work by this research team suggests that these compounds may reduce inflammation and oxidative stress and may improve the way the body handles sugars and fats, processes that are also altered in Alzheimer's disease.
This study will test whether consuming olive oils that contain these compounds delays the progression from prodromal Alzheimer's disease to dementia.
A total of 120 adults aged 50 to 80 years with prodromal Alzheimer's disease will take part at three public hospitals in southern Spain. Participants will be assigned by chance to one of three groups and will consume 55 mL per day of one of three oils for 12 months: olive oil enriched with oleanolic acid, pomace olive oil (which naturally contains both compounds), or a standard commercial olive oil with very low levels of these compounds. Neither the participants nor the staff assessing them will know which oil each person is receiving.
Participants will attend study visits at the start of the study and after 6 and 12 months. At these visits they will complete memory and thinking tests, a physical and nutritional assessment, and blood and urine tests.
NEUROLEA is a multicenter, randomized, double-blind, controlled dietary intervention trial coordinated by the Instituto de la Grasa (CSIC). Participants will be recruited at the Neurology Units of Hospital Universitario Virgen del Rocío, Hospital Universitario Reina Sofía and Hospital Universitario de Valme.
Study oils. High-purity crystalline oleanolic acid (>95%) will be obtained from olive leaves following a procedure developed by the research team (Spanish Patent ES2160553) and used to prepare an oleanolic acid-enriched olive oil (600 mg/kg) according to European Patent EP18382510. A commercial olive oil 0.4° will serve as the control oil, as it has the same fatty acid composition as the other oils but a very low content of minor bioactive components. Pomace olive oil, which naturally contains oleanolic acid and erythrodiol, will be purchased from local markets. Oil composition will be verified by gas chromatography and differential scanning calorimetry before the intervention begins.
Randomization and blinding. Allocation will follow computer-generated random numbers prepared by the trial coordinator. Participants, clinical and nutritional research staff, and the neuropsychologists scoring the cognitive assessments will be blinded to group assignment.
Sample size. Thirty-four participants per arm are required for 90% power to detect a 10% reduction in dementia incidence in the functional oil arms compared with a 25% incidence in the control arm over 12 months (alpha 0.05). Allowing for up to 15% attrition in a long-term dietary intervention, the target is 40 participants per arm (120 in total).
Intervention and follow-up. Participants will consume 55 mL/day of the assigned oil, preferably raw and distributed across the three main meals, for 12 months. Adherence will be assessed with the self-reported Haynes-Sackett compliance test and by return of empty bottles, methods previously used by this team in the PREDIABOLE and OLTRAD trials. Participants and their caregivers will receive general healthy-eating guidance throughout the study.
Assessments. Evaluations will be performed at baseline and after 6 and 12 months, and will include a comprehensive neuropsychological battery, clinical examination, anthropometry and body composition by bioimpedance, dietary intake and diet quality questionnaires, and fasting blood and urine sampling. Serum concentrations of oleanolic acid and erythrodiol will be measured by HPLC-MS to verify exposure.
Mechanistic analyses. Beyond the clinical endpoints, the trial will examine circulating markers of lipid and glucose metabolism, oxidative stress and inflammation, and advanced glycation end product metabolism, together with the expression of related genes in peripheral blood mononuclear cells. Blood-based markers of Alzheimer's disease pathology (p-tau 217, neurofilament light chain, glial fibrillary acidic protein, and the amyloid beta 42/40 ratio) will be quantified at baseline and 12 months.
Data will be managed in REDCap and stored in pseudonymized form in accordance with the General Data Protection Regulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women aged 50 to 80 years Diagnosis of prodromal Alzheimer's disease, meeting all of the following: memory complaints corroborated by a reliable informant; (MMSE) total score between 22 and 30; Free and Cued Selective Reminding Test (FCSRT, picture version) total recall score of 46 or less; Clinical Dementia Rating Global Score (CDR-GS) of 0.5; functional independence in activities of daily living (Functional Activities Questionnaire total score of 8 or less); plasma p-tau 217 above 0.45 pg/mL measured by the Lumipulse method Ability and willingness to attend scheduled visits at the study center Adequate visual and auditory capacity to complete study evaluations Educational level sufficient to read and write Written
Exclusion Criteria:
Absence of a reliable informant Evidence, based on medical history or clinical evaluation, of a neurological condition other than Alzheimer's disease that could account for the cognitive impairment , advanced or unstable systemic disease that may interfere with cognitive evaluation Severe psychiatric disorders, including schizophrenia, bipolar disorder or active major depression History of alcohol or psychotropic substance abuse Pre-existing intellectual disability that precludes neuropsychological evaluation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will consume 55 mL/day of olive oil enriched with oleanolic acid (600 mg/kg) for 12 months, preferably raw and distributed across the three main meals.
Dietary Supplement: Oleanolic acid-enriched olive oil
Participants will consume 55 mL/day of commercial pomace olive oil, which naturally contains oleanolic acid (180 mg/kg) and erythrodiol (670 mg/kg), for 12 months, preferably raw and distributed across the three main meals.
Dietary Supplement: Pomace olive oil
Participants will consume 55 mL/day of commercial olive oil 0.4°, which has the same fatty acid composition but a very low content of minor bioactive components, for 12 months, preferably raw and distributed across the three main meals.
Dietary Supplement: Commercial olive oil 0.4 degrees
Olive oil enriched with oleanolic acid (600 mg/kg), 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.
Commercial pomace olive oil, naturally containing oleanolic acid (180 mg/kg) and erythrodiol (670 mg/kg), 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.
Commercial olive oil 0.4°, with the same fatty acid composition but a very low content of minor bioactive components, 55 mL/day for 12 months, consumed preferably raw and distributed across the three main meals.
Conversion from prodromal Alzheimer's disease to dementia
Proportion of participants converting to dementia, defined as a change in the Clinical Dementia Rating Global Score (CDR-GS) from 0.5 at baseline to 1 or higher. The CDR-GS ranges from 0 to 3, with higher scores indicating greater dementia severity
Time frame: Baseline to 12-months
Change in Clinical Dementia Rating Sum of Boxes (CDR-SB)
CDR-SB total score ranges from 0 to 18, with higher scores indicating more severe cognitive impairment.
Time frame: Baseline to 12-months
Change in Mini-Mental State Examination (MMSE) score
MMSE total score ranges from 0 to 30, with higher scores indicating better global cognitive performance
Time frame: Baseline to 12-months
Change in Mild Behavioral Impairment Checklist (MBI-C) score
MBI-C assesses behavioral and psychological symptoms; higher scores indicate more severe symptoms
Time frame: Baseline to 12-months
Change in Functional Activities Questionnaire (FAQ) score
FAQ total score ranges from 0 to 30, with higher scores indicating greater functional impairment
Time frame: Baseline to 12-months
Change in lipid metabolism biomarkers
Serum concentrations of total triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, apolipoprotein A1 and apolipoprotein B
Time frame: Baseline, 6 months and 12 months
Change in glucose metabolism and insulin sensitivity biomarkers
Plasma glucose, insulin, glycated hemoglobin (HbA1c), HOMA-IR index and Quantitative Insulin Sensitivity Check Index (QUICKI)
Time frame: Baseline, 6 months and 12 months
Change in plasma lipid classes
Cholesterol esters, triglycerides, diglycerides, free cholesterol, monoglycerides, phospholipids and ceramides determined by HPLC-MS.
Time frame: Baseline and 12 months
Change in oxidative stress markers
Reduced and oxidized glutathione (GSH, GSSG), Nrf2 levels, activities of superoxide dismutase, catalase and heme oxygenase-1, reactive oxygen species production and malondialdehyde.
Time frame: Baseline, 6 months and 12 months
Change in inflammation markers
NF-kB p65 and proinflammatory cytokines (TNF-alpha and IL-1beta) measured in plasma or serum.
Time frame: Baseline, 6 months and 12 months
Change in circulating advanced glycation end products and dicarbonyl compounds and parameters related to their metabolism
Time frame: Baseline, 6 months and 12 months
Change in blood biomarkers of Alzheimer's disease pathology
Plasma p-tau 217, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and the amyloid beta 42/40 ratio.
Time frame: Baseline and 12 months
Serum concentrations of oleanolic acid and erythrodiol
Time frame: Baseline, 6 months and 12 months
Plan to share: Yes — De-identified individual participant data underlying published results will be made available in institutional repositories, in accordance with the data management plan of the project and with international standards for the documentation of clinical study data.
Supporting information: Study protocol, Informed consent form
Time frame: Data will become available after completion of the project and publication of the main results, and will remain accessible for at least five years thereafter.
Access criteria: Requests for access should be submitted to the principal investigator by e-mail, including a description of the proposed research question and analysis plan. Requests will be evaluated by the study investigators. Access to de-identified individual participant data and to the supporting documents will be granted to researchers whose proposal is considered methodologically sound and consistent with the consent given by study participants, subject to a signed data access agreement.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 21 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish National Research Council